06 | Integrated cancer control

Work package 6 enables people to access the best and most comprehensive pathways for cancer care near to where they live.

This work package gives recommendations for the organisation of comprehensive cancer services and best care for the population in any given area, thus achieving greater equity.

In many areas, the integration of medical services is essential for the most effective use of available resources. The work package focuses especially on how to supplement the concept of comprehensive cancer center (CCC) with the concept of a comprehensive cancer care network (CCCN).

Comprehensive cancer care services will have synergy with all relevant institutions that have complementary expertise. This synergy will cause the following benefits:

• an advantage for clinical, translational and basic cancer research,
• effective operation by exploiting complementary expertise and avoiding unnecessary duplications, and
• a seamless sustainable pathway of care nearer their homes for all patients.

In addition, the work package will examine how CCCN:

1. flexibly adjusts the interaction between primary, secondary and tertiary units to best fit the cancer control needs of individual member states, and
2. lend itself to the creation/integration of trans-national networks.

The work package will set the principles for how the CCCN should be organised. The aim is to

• promote the optimal use of advanced technologies;
• make innovative clinical trials accessible to entire population on a certain area;
• identify within the CCCN the most suitable unit for the management of rare and complex tumors;
• promote within the CCCN common infrastructures, and
• provide a forum for regular consultation among professionals. 

More information

The Tumour Institute of Tuscany (ITT), RT-ITT, Italy, is the leader of the work package 6. For further information, contact Fotios Loupakis at [email protected] 

Associated partners involved in the work package: 

• Institute of Biostatistics and Analyses at the Faculty of Medicine and the Faculty of Science of the Masaryk University, (MU), [email protected] (Czech Republic)
• The French National Cancer Institute, INCA, [email protected] (France)
• Deutsche Krebsgesellschaft e.V., DKG, [email protected] (Germany)
• Department of Health, DOH, [email protected] (Ireland)
• Fondazione IRCCS Istituto Nazionale dei Tumori, INT, [email protected] (Italy)
• The Tumour Institute of Tuscany (ITT), RT-ITT, [email protected] (Italy)
• Norwegian University of Science and Technology, NTNU, [email protected] (Norway)